Track ALNY's AI-powered predictions, market trends, and investment insights.
You don't hold ALNY in your mock portfolio yet.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get StartedThe company’s high PE ratio of 70.89 and positive EPS of 3.99 indicate that Alnylam is profitable but priced for strong future growth. Such a premium valuation suggests investors expect continued revenue expansion and margin improvement, but it also leaves limited room for execution missteps. Without detailed revenue and margin history, the profile looks like a typical high-growth biotech transitioning into sustained profitability, with risk skewed to how well it can justify its valuation.
At $282.85, Alnylam trades materially below its 200-day moving average of $377.74, indicating a pronounced downtrend or at least a period of technical weakness. The modest 1.4% decline over the last month understates the broader technical damage implied by such a large gap to the long-term average. Combined with a rich valuation, the technical setup currently skews more bearish than supportive in the near term.
Alternative data for Alnylam is broadly constructive, particularly the sharp increase in job openings, which often signals investment in growth, R&D, and commercialization capacity. Web traffic is moderate but not clearly deteriorating based on the data provided, while social media followership—especially on LinkedIn—is large and growing modestly, consistent with a strong employer brand and professional engagement. Overall, these signals point toward internal expansion and stable external interest, supportive of a positive medium-term outlook.
Alnylam Pharmaceuticals presents a mixed picture: operational and alternative data suggest a company investing for growth and maintaining strong professional visibility, while the stock trades in a clear technical downtrend and at a premium valuation. The combination of high expectations (via a rich PE), price weakness versus the 200-day moving average, and positive internal growth signals leads to an overall neutral stance, with outcomes highly dependent on execution and pipeline progress. Investors may see upside if growth justifies the valuation and the chart stabilizes, but current technicals and pricing leave meaningful downside risk if expectations are not met.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Alnylam Pharmaceuticals (ALNY) is trading at $282.85 on the NASDAQ, down 2.3% in today's session, with volume running at approximately 1.4 million shares. The company carries a $37.8 billion market cap, reflecting its standing as the leading commercial-stage player in RNA interference therapeutics. With approved products including ONPATTRO and GIVLAARI already generating revenue, Alnylam is no longer purely a pipeline story — it is a company navigating the transition from biotech innovator to durable biopharmaceutical franchise. The single-day pullback warrants attention but does not alter the underlying structural thesis.
TrendEdge's AI model assigns ALNY a score of 7 out of 10, placing it in constructive territory without signaling aggressive conviction. The score reflects Alnylam's commercially validated RNAi platform, diversified pipeline across genetic medicines, cardio-metabolic, and CNS/ocular indications, and a meaningful hiring footprint — 253 active job postings suggest continued operational build-out. A score of 7 typically indicates positive underlying fundamentals tempered by valuation complexity or near-term execution risk. For a $37.8 billion biotech, sustaining that score depends heavily on pipeline progression and revenue scaling from existing approvals.
Key catalysts to monitor for ALNY in 2026 include clinical readouts across its cardio-metabolic and CNS pipeline, commercial uptake trajectory for its approved therapies, and competitive dynamics in the RNAi space. The 253 active job postings indicate the company is investing in operational infrastructure, which can signal confidence in near-term growth. Primary risks include clinical trial setbacks, pricing pressure in rare disease markets, and the capital-intensive nature of expanding into new therapeutic areas. The 2.3% single-session decline is worth tracking if it continues on elevated volume.
Unlock comprehensive alternative data signals to make better investment decisions
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
Web Traffic
74,693
Twitter Followers
17,390
Instagram Followers
2,784
YouTube Subscribers
2,940
LinkedIn Followers
287,555
Job Postings
256
LinkedIn Employees
2,854
News Mentions
0
Key Metrics
